A well-written protocol does not guarantee a shared understanding of how to execute it. Clinical trial professionals rarely approach a new study with a blank
A well-written protocol does not guarantee a shared understanding of how to execute it. Clinical trial professionals rarely approach a new study with a blank
The earliest signs of trial risk may appear before the first patient is ever enrolled. Training completion tells you who finished. It does not necessarily
A new conversation about clinical trial performance starts here. Published by Applied Clinical Trials and sponsored by ArcheMedX, the new podcast series explores a simple
The clinical trials industry is moving fast on AI. The assumption underneath most of that momentum, that better tooling will narrow the performance gap between site teams, deserves a direct challenge. AI does not close the readiness divide. Applied to the work of running a trial, it is more likely to widen it.
Most protocol deviations start as human problems, not operational ones, but risk-based monitoring typically relies on lagging indicators that arrive too late to prevent these
By leveraging the Fresh Start Effect at site initiation and shifting from passive training to demonstrated readiness, sponsors and CROs can turn trial launch into a powerful multiplier for early performance, compliance, and execution quality.
When confidence outpaces competence in clinical research, the risks can be hidden…and costly for trial sponsors
Clinical trials aren’t just more complex. They’re harder to manage, more expensive to run, and increasingly exposed to delay and disruption. Sponsors willing to take a different path can deliver faster, higher-quality trials at a lower cost.
I. Introduction: Two Conferences, One Reality This past week at DIA and BIO offered two very different views of the clinical research world. DIA felt
In clinical research, where accuracy, coordination, and compliance are non-negotiable, the greatest threat isn’t always a lack of knowledge. Sometimes, it’s the mistaken belief that
Clinical trials professionals face a host of challenges: for some, it’s the complexity in protocol design, for many it’s lagging enrollment rates, and for others it’s the site burden that’s inherent to change management.
The compounding benefits of effective training cannot be overstated. When clinical research associates (CRAs) and site staff are thoroughly prepared, they engage more deeply with the trial protocols, ask more insightful questions, and more proactively anticipate challenges.
ArcheMedX helps life sciences and healthcare organizations to better equip, evaluate, and predict team and clinician performance
